Valuation: ZIM Laboratories Limited

Market Cap 6.09B 63.81M 55.82M 51.48M 47.63M 90.41M 91.92M 617M 242M 2.99B 240M 234M 10.36B P/E 2025
32.1x
P/E 2026 50.3x
Enterprise Value 6.95B 72.86M 63.73M 58.77M 54.38M 103M 105M 704M 276M 3.42B 274M 268M 11.83B EV / Sales 2025
1.34x
EV / Sales 2026 1.09x
Free-Float
28.65%
Yield 2025 *
-
Yield 2026 -
1 day-1.98%
1 week-9.00%
Current month-8.49%
1 month+9.96%
3 months+59.54%
6 months+68.27%
Current year+58.23%
1 week 113.75
Extreme 113.75
123.15
1 month 107
Extreme 107
133.95
Current year 59.72
Extreme 59.72
133.95
1 year 59.72
Extreme 59.72
133.95
3 years 59.72
Extreme 59.72
151.75
5 years 36.37
Extreme 36.3667
151.75
10 years 14
Extreme 14
151.75
Manager TitleAgeSince
Chief Executive Officer - 2001-12-31
Director of Finance/CFO - 2019-03-31
Director of Finance/CFO - 1990-12-31
Director TitleAgeSince
Chairman - 1989-12-31
Director/Board Member - 1990-12-31
Director/Board Member - 2012-12-31
Change 5-day change 1-year change 3-year change Capi.($)
-1.98%-9.00%-0.39%+7.51% 64.9M
+2.67%+3.88%+15.92%+87.19% 47.31B
-0.81%+3.80%+67.17%+112.23% 36.04B
+0.66%-1.06%-3.16%+41.21% 12.08B
+0.96%+4.49%+17.88%+99.06% 11.96B
+0.38%+1.95%+34.36%+123.93% 9.05B
-0.08%-0.91%+17.07%+43.71% 6.92B
-1.61%+3.42%+58.05%-3.09% 7.19B
+1.96%+4.87%+23.86%+228.94% 6.55B
-2.19%+2.95%-21.76%+7.68% 5.9B
Average +0.02%-0.29%+20.90%+74.84% 14.31B
Weighted average by Cap. +0.76%+1.66%+29.53%+89.47%

Financials

2025 2026
Net sales 3.79B 39.72M 34.75M 32.04M 29.65M 56.27M 57.21M 384M 150M 1.86B 149M 146M 6.45B 3.74B 39.22M 34.31M 31.64M 29.28M 55.57M 56.5M 379M 149M 1.84B 147M 144M 6.37B
Net income 122M 1.27M 1.11M 1.03M 951K 1.81M 1.84M 12.31M 4.83M 59.74M 4.78M 4.68M 207M 58.38M 612K 535K 493K 457K 867K 881K 5.91M 2.32M 28.67M 2.3M 2.25M 99.31M
Net Debt 1.16B 12.13M 10.61M 9.78M 9.05M 17.18M 17.47M 117M 45.93M 568M 45.53M 44.54M 1.97B 863M 9.04M 7.91M 7.29M 6.75M 12.81M 13.02M 87.35M 34.24M 424M 33.94M 33.21M 1.47B
Logo ZIM Laboratories Limited
ZIM Laboratories Limited is a pharmaceutical company. The Company develops, manufactures and supplies oral, solid differentiated generic pharmaceutical formulations and pre-formulation intermediaries (PFI) in various therapeutic segments. Its delivery solutions cover product conceptualization product development, filing for registration, manufacture, and supply of various pharmaceutical formulations. It is developing products in various therapeutic segments like, central nervous system, anti-biotic and anti-infective, gastrointestinal, cardiovascular, analgesic/pain management, urology and vitamins, minerals, and dietary supplements. Its technological capabilities include drug release modification, solubility and stability enhancement, taste masking and dosage form transformation. Its product offerings include finished formulations and pre-formulations intermediates, which include granules, pellets, taste-masked powders, dry suspensions, tablets, capsules, and oral thin films.
Employees
632
Date Price Change Volume
26-07-09 113.75 -1.98% 987
26-07-08 ₹116.05 -1.78% 1,878
26-07-07 ₹118.15 -1.99% 857
26-07-06 ₹120.55 -1.99% 732
26-07-03 ₹123.00 -0.08% 2,591
  1. Stock Market
  2. Stocks
  3. ZIMLAB Stock